Jerini AG Reports First Quarter 2009 Financial Results

Berlin, Germany, May 15, 2009 - Jerini AG (FSE:JI4) reported
financial results for the first quarter ended March 31, 2009. Under
International Financial Reporting Standards (IFRS), revenues for the
three-month period increased by 49.9 percent to EUR 1.8 million from
EUR 1.2 million for the same period in 2008, mainly due to product
sales from Firazyr® of EUR 0.4 million in the first quarter 2009.

First quarter research and development expenses decreased to EUR 3.5
million (prior year period: EUR 4.7 million). General and
administrative expenses decreased to EUR 1.1 million (prior year
period: EUR 2.3 million). Marketing and sales expenses decreased to
EUR 1.3 million (prior year period: EUR 1.8 million), as a result of
expenses related to product launch preparation in the first quarter
of 2008. Consequently, loss from continuing operations before tax
and finance cost (EBIT) decreased to EUR 3.9 million (prior year
period: EUR 7.5 million). For the three-month period ended March 31,
2009, net loss from continuing operations amounted to EUR 2.7 million
and net loss amounted to EUR 4.3 million (prior year period: EUR 7.2
million and EUR 8.8 million). Loss per share amounted to EUR 0.07
(prior year period: EUR 0.17), while loss per share from continuing
operations amounted to EUR 0.05 (prior year period: EUR 0.14).

Cash used in operating activities as of March 31, 2009 totaled EUR
6.3 million
(prior year period: EUR 9.5 million). Net cash burn for the first
three months of 2009 amounted to EUR 6.4 million (prior year period:
EUR 9.9 million). Net cash burn is calculated by the addition of cash
used in operating activities (EUR 6.3 million) and cash used in
investing activities (EUR 0.1 million), as disclosed in the unaudited
consolidated cash flow statements for the three-month period ended
March 31, 2009. As of March 31, 2009, cash and cash equivalents
amounted to EUR 18.0 million, compared to EUR 2.6 million as of
year-end 2008.

Outlook
Jerini's Shareholders' Meeting will take place on June 16, 2009.
Shire Deutschland Investments GmbH currently holds more than 98
percent of Jerini's outstanding shares. Jerini AG has received a
formal request, according to section 327a of the German Stock
Corporation (AktG), from Shire Deutschland Investments GmbH to pass a
resolution at Jerini's General Shareholders' Meeting calling for the
transfer of shares held by Jerini's minority shareholders to Shire
Deutschland Investments GmbH (so-called "Squeeze Out"). As
compensation, minority shareholders will receive payment of adequate
cash compensation from Shire Deutschland Investments GmbH.

As a result of Jerini's meeting and discussions with the US Food and
Drug Administration (FDA) in December 2008, plans are underway to
initiate a placebo-controlled confirmatory Phase III trial in the
third quarter of 2009. After this trial has been completed, Jerini
will submit a complete response to the FDA's "Not Approvable" letter
received in April 2008.

Progress continues on the divestment of Jerini's preclinical
programs.

About Jerini AG
Jerini is a pharmaceutical company based in Berlin, Germany. In July
2008, the company received marketing approval from the European
Commission for Firayzr® in the treatment of acute attacks of
hereditary angioedema (HAE). On July 3, 2008, Jerini and Shire plc's
German wholly-owned indirect subsidiary Shire Deutschland Investments
GmbH ("Shire") entered into a business combination agreement
regarding a strategic partnership. Jerini is now a subsidiary of
Shire plc and a member of the Shire group of companies. Shire
currently holds more than 98 percent of Jerini's shares and has
requested that a resolution be passed at Jerini's 2009 General
Shareholders' Meeting calling for the transfer of the remaining
shares held by Jerini's minority shareholders.

ISIN: DE0006787476

For questions, please contact:
Stacy Wiedenmann
Director Investor Relations &
Corporate Communications
Jerini AG
Invalidenstr. 130
10115 Berlin
T + 49 - 30 - 97893 - 285
X + 49 - 30 - 97893 - 599
wiedenmann@jerini.com

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.